These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20155405)

  • 1. The role of PET-CT in the differential diagnosis of thymic mass after treatment of patients with lymphoma.
    Ustaalioglu BB; Seker M; Bilici A; Canpolat N; Yıldirim E; Kefeli U; Ustaalioglu R; Yilmaz BE; Salepci T; Ozdemir N; Gumus M
    Med Oncol; 2011 Mar; 28(1):258-64. PubMed ID: 20155405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma].
    Zhen ZJ; Sun XF; Xia Y; Wang ZH; Ling JY
    Ai Zheng; 2006 Apr; 25(4):471-5. PubMed ID: 16613683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FDG PET in malignant lymphoma: significance of positive findings.
    Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S
    Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cervical lymph node hyperplasia on [(18)F]-fluorodeoxyglucose positron emission tomography/computed tomography scan after treatment of children and adolescents with malignant lymphoma.
    Hu YY; Zhang X; Long W; Lin XP; Zhang YR; Li YH; Xiao ZZ; Zheng RL; Liang PY; Fan W
    Eur J Radiol; 2015 Jul; 84(7):1378-82. PubMed ID: 25882963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of flourine-18 fluorodeoxyglucose positron emission tomography in thymic pathology.
    El-Bawab H; Al-Sugair AA; Rafay M; Hajjar W; Mahdy M; Al-Kattan K
    Eur J Cardiothorac Surg; 2007 Apr; 31(4):731-6. PubMed ID: 17293120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma.
    Zinzani PL; Tani M; Trisolini R; Fanti S; Stefoni V; Alifano M; Castellucci P; Musuraca G; Dalpiaz G; Alinari L; Marchi E; Fina M; Pellegrini C; Farsad M; Cancellieri A; Busca A; Canini R; Pileri S; Baccarani M; Boaron M
    Haematologica; 2007 Jun; 92(6):771-7. PubMed ID: 17550849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT.
    Mikhaeel NG; Timothy AR; O'Doherty MJ; Hain S; Maisey MN
    Leuk Lymphoma; 2000 Nov; 39(5-6):543-53. PubMed ID: 11342337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation between rebound thymic hyperplasia and thymic relapse after chemotherapy in pediatric Hodgkin lymphoma.
    Franke FC; Damek A; Steglich J; Kurch L; Hasenclever D; Georgi TW; Wohlgemuth WA; Mauz-Körholz C; Körholz D; Kluge R; Landman-Parker J; Wallace WH; Fosså A; Vordermark D; Karlen J; Fernández-Teijeiro A; Cepelova M; Klekawka T; Attarbaschi A; Ceppi F; Hraskova A; Uyttebroeck A; Beishuizen A; Dieckmann K; Leblanc T; Moellers M; Buerke B; Stoevesandt D
    Pediatr Blood Cancer; 2023 Aug; 70(8):e30421. PubMed ID: 37243889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.
    Pelosi E; Pregno P; Penna D; Deandreis D; Chiappella A; Limerutti G; Vitolo U; Mancini M; Bisi G; Gallo E
    Radiol Med; 2008 Jun; 113(4):578-90. PubMed ID: 18414808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
    Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
    J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
    Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
    Qiu L; Chen Y; Wu J
    Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactive thymic hyperplasia following chemotherapy for children with lymphoma: computed tomography may be able to provide valuable information to avoid over-treatment.
    Tian L; Cai PQ; Cui CY; Mo YX; Gong X; Fan W
    Eur J Cardiothorac Surg; 2015 May; 47(5):883-9. PubMed ID: 25079775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission.
    Morbelli S; Capitanio S; De Carli F; Bongioanni F; De Astis E; Miglino M; Verardi MT; Buschiazzo A; Fiz F; Marini C; Pomposelli E; Sambuceti G
    Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):232-239. PubMed ID: 26283504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
    Querellou S; Valette F; Bodet-Milin C; Oudoux A; Carlier T; Harousseau JL; Chatal JF; Couturier O
    Ann Hematol; 2006 Nov; 85(11):759-67. PubMed ID: 16871391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computed tomography, magnetic resonance imaging and positron emission tomography in non-Hodgkin's lymphoma.
    Rodriguez M
    Acta Radiol Suppl; 1998; 417():1-36. PubMed ID: 9645167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
    Reinhardt MJ; Herkel C; Altehoefer C; Finke J; Moser E
    Ann Oncol; 2005 Sep; 16(9):1524-9. PubMed ID: 15946979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up?
    Petrausch U; Samaras P; Veit-Haibach P; Tschopp A; Soyka JD; Knuth A; Hany TF; Mischo A; Renner C; Schaefer NG
    Ann Oncol; 2010 May; 21(5):1053-7. PubMed ID: 19914963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas.
    Hernandez-Pampaloni M; Takalkar A; Yu JQ; Zhuang H; Alavi A
    Pediatr Radiol; 2006 Jun; 36(6):524-31. PubMed ID: 16622665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.